Treatment of lung diseases based on stratification of polygenic scores associated with therapeutic response

By calculating FEV1-PS to guide therapeutic agent dosage, the method addresses the challenge of predicting subject responses to lung disease treatments, enhancing treatment efficacy through personalized dosing.

JP2024542508APending Publication Date: 2024-11-15REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024530034
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-30
Filing Date
2022-11-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Current methods struggle to predict which subjects will respond to therapeutic agents for lung diseases such as asthma and COPD, making it difficult to administer effective treatments.

Method used

Determine a subject's FEV1 polygenic score (FEV1-PS), which is a collection of genetic variants associated with pre-bronchodilator FEV1, to guide the dosage of therapeutic agents like bronchodilators, IL-33 antagonists, and interleukin-4 receptor alpha antagonists.

Benefits of technology

This approach allows for personalized treatment by identifying subjects likely to respond well to standard doses or requiring higher doses, thereby improving treatment efficacy and reducing ineffective treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542508000001_ABST
    Figure 2024542508000001_ABST
Patent Text Reader

Abstract

The disclosure provides methods for identifying subjects having or at risk of developing a pulmonary disease who will respond favorably to treatment with a therapeutic agent that treats or inhibits a pulmonary disease, such as dupilumab, an inhaled corticosteroid (ICS), or a long-acting beta agonist (LABA), and methods for treating a subject having a pulmonary disease with a therapeutic agent that treats or inhibits a pulmonary disease, such as dupilumab, an ICS, or a LABA, and determining or having determined the subject's FEV1 polygenic score (FEV1-PS).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] REFERENCE TO SEQUENCE LISTING This application contains a Sequence Listing that has been submitted electronically as an XML file of 16 kilobytes in size under the title 381203562SEQ, created on November 28, 2022. This Sequence Listing is incorporated herein by reference. The present disclosure relates to the field of therapeutic treatment of pulmonary diseases. More specifically, the disclosure relates to methods for identifying subjects with pulmonary diseases who will respond to a therapeutic agent that treats or inhibits the pulmonary disease. [Background technology]

[0002] Asthma is an inflammatory disease of the airways of the lungs. The condition is characterized by variable and recurrent symptoms, reversible airflow obstruction, and easily provoked bronchospasm. Diagnosis of asthma may include spirometry pulmonary function testing, including determination of forced expiratory volume in 1 second (FEV1) and peak expiratory flow, as well as assessment of annualized exacerbation rate. Treatment of asthma involves administration of fast-acting or long-term effective medications. While salbutamol and albuterol are the mainstay of fast-acting medications, inhaled corticosteroids (ICS) have been the cornerstone of long-term treatment for many years. More recently, antibodies such as mepolizumab, dupilumab, and omalizumab have been used in association with certain types of asthma. However, it is difficult to predict whether a given subject will respond to a given antibody therapy. Genome-wide association studies (GWAS) related to asthma have been conducted (Moffat et al., N. Engl. J. Med., 2010, 363, 1211-1221). However, Moffat does not disclose a method for identifying subjects with pulmonary disease who respond to therapeutic agents that treat or inhibit pulmonary disease.

[0003] Chronic obstructive pulmonary disease (COPD) is characterized in part by airflow limitation, emphysema, and chronic bronchitis. COPD is frequently exacerbated by daily activities, making everyday tasks difficult. Tobacco smoke is the main risk factor, but other factors include pollution, genetics, and exposure to dust and chemicals in the workplace. Diagnosis of COPD frequently involves spirometry, including determining the patient's FEV1 value. Current treatments include smoking cessation, short-acting bronchodilators, phosphodiesterase-4 inhibitors, corticosteroids, and, in severe cases, antibiotics. However, it is difficult to predict whether a patient will respond to a given treatment. Summary of the Invention

[0004] The disclosure provides a method of treating a subject having or at risk of developing a pulmonary disease with a therapeutic agent that treats or inhibits the pulmonary disease, comprising determining or having determined the subject's FEV1 polygenic score (FEV1-PS), where FEV1-PS comprises a collection of multiple genetic variants associated with pre-bronchodilator FEV1, and administering or continuing to administer a standard dose of the therapeutic agent that treats or inhibits the pulmonary disease if the subject's FEV1-PS is equal to or greater than a threshold FEV1-PS, or administering a greater than standard dose of the therapeutic agent that treats or inhibits the pulmonary disease if the subject's FEV1-PS is less than the threshold FEV1-PS.

[0005] The disclosure also provides a method of determining whether a subject having or at risk of developing a pulmonary disease will respond adequately to treatment with a therapeutic agent that treats or inhibits the pulmonary disease, comprising determining or having determined the subject's FEV1 polygenic score (FEV1-PS), where the FEV1-PS comprises a collection of multiple genetic variants related to pre-bronchodilator FEV1, and where an FEV1-PS equal to or greater than a threshold FEV1-PS indicates that the subject will respond adequately to treatment with a therapeutic agent that treats or inhibits the pulmonary disease at a standard dose, or an FEV1-PS below the threshold FEV1-PS indicates that the subject will not respond adequately to treatment with a therapeutic agent that treats or inhibits the pulmonary disease at a standard dose.

[0006] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several features of the present disclosure. [Brief description of the drawings]

[0007] [Figure 1A] Results show that FEV1-PS was significantly associated with increased change in FEV1 at week 12 in both dupilumab- and placebo-treated European subjects (Panel A), with dupilumab-treated patients in the highest quartile showing the greatest improvement in FEV1 compared with placebo-treated patients (Panel B). [Figure 1B] Same as above. [Diagram 2] We show that FEV1-PS was significantly associated with increased longitudinal change in FEV1 in both dupilumab- and placebo-treated European subjects; in both dupilumab- and placebo-treated patients, patients with the highest FEV1-PS had the greatest FEV1 improvement. [Figure 3A] (Panels A and B) show that FEV1-PS was not associated with differences in annualized exacerbation rates in both dupilumab- and placebo-treated European subjects. [Figure 3B] Same as above. [Figure 4A](Panels A and B) show that FEV1-PS determined from European samples in UKBiobank was significantly associated with pre-bronchodilator FEV1 in the GHS_GSA Europe sample. [Figure 4B] Same as above. [Diagram 5] FIG. 1 shows genome-wide FEV1-PS in GHS_GSA European subjects, showing association with exacerbations in asthma patients. [Figure 6A] Genome-wide FEV1-PS in GHS_GSA European subjects for asthma (Panel A) and COPD (Panel B). [Figure 6B] Same as above. [Figure 7] FIG. 1 shows genome-wide FEV1-PS (source dataset: GWAS from FEV1 GWAS in subjects without asthma or COPD) is associated with exacerbations in asthma patients. [Figure 8A] Figure 1 Genome-wide FEV1-PS in GHS_GSA European patients (source dataset: GWAS from FEV1 GWAS in subjects without asthma or COPD) shows association of FEV1-PS to asthma (Panel A) and COPD (Panel B). [Figure 8B] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] Genetic factors may play an important role in the risk of developing disease and may potentially affect how an individual responds to drug treatment. Polygenic risk scores (PRS) combine information from multiple genetic variants derived from disease association studies to create a single composite quantitative measure for each individual that reflects the individual's genetically derived disease risk. Individuals with more risk alleles for a particular disease will have a higher PRS than individuals with fewer alleles for the same particular disease. Risk can be assessed at several thresholds, such as percentiles, standard deviation units of population distribution, or absolute values. The present disclosure generally relates to the unexpected discovery that stratifying subjects by FEV1-PS is useful for identifying subjects who are more likely to respond to therapeutic agents that treat or inhibit lung disease, including, but not limited to, bronchodilators, IL-33 antagonists, interleukin-4 receptor alpha antagonists, and / or interleukin-13 receptor antagonists.

[0009] Spirometry is a common breathing test that measures the maximum force of a patient's breathing after inspiration and expiration. Patients with asthma or other breathing problems can have spirometry done before and after bronchodilators to test the effectiveness of medication for their breathing problems.

[0010] FEV1 is measured by spirometry and is defined as the forced expiratory volume in the first second. The amount of air expelled in one second after a deep breath is an important measure of lung function. FEV1-PS is a collection of multiple genetic variants associated with the lung metric FEV1. FEV1-PS is calculated, for example, in a representative hypothetical GWAS in Table 2. The GWAS may have identified four genetic variants associated with FEV1. Each of the genetic variants may be associated with one or more genes. Values ​​such as odds ratios can be calculated for each individual genetic variant. The FEV1-PS of a particular subject can be determined by multiplying the logarithm of the individual odds ratios for each variant by the numerical effect allele (which is the number of copies of the genetic variant in the genome, i.e., either 0, 1, or 2), and then summing the resulting values. For illustrative purposes, see Table 2.

[0011] Various terms relating to aspects of the present disclosure are used throughout the specification and claims. Unless otherwise indicated, such terms are to be given their ordinary meaning in the art. Other terms that are specifically defined are to be interpreted in a manner consistent with the definitions set forth herein.

[0012] Unless expressly stated otherwise, no method or aspect set forth herein is intended to be construed as requiring that its steps be performed in a particular order. Thus, unless specifically stated by a method claim in the claims or description that the steps should be limited to a particular order, no order is intended to be imposed in any respect. This also applies to any possible implicit criteria of interpretation, including logical matters regarding the arrangement of processes or work flows, general meanings derived from grammatical constructions or punctuation, or the number or type of aspects described herein.

[0013] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. As used herein, the term "about" means that the recited numerical values ​​are approximate and that small variations will not significantly affect the practice of the disclosed embodiments. When numerical values ​​are used, unless otherwise indicated by context, the term "about" means that the numerical values ​​can vary by ±10% and remain within the range of the disclosed embodiments.

[0014] As used herein, the term "subject" includes any animal, including mammals. Mammals include, but are not limited to, farm animals (e.g., horses, cows, pigs), pet animals (e.g., dogs, cats), laboratory animals (e.g., mice, rats, rabbits), and non-human primates (e.g., apes and monkeys). In some embodiments, the subject is a human. In some embodiments, the subject is a patient under the care of a physician.

[0015] The present disclosure provides a method of treating a subject having a pulmonary disease with a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist. In some embodiments, the subject having a pulmonary disease is treated with dupilumab. The method includes determining or having determined the subject's therapeutic polygenic score (FEV1-PS). The FEV1-PS includes a collection of multiple genetic variants associated with pre-bronchodilator FEV1. The method includes administering or continuing administration of dupilumab (or generally a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist) at a standard dose when the subject's FEV1-PS is equal to or greater than a threshold FEV1-PS. The methods also include administering dupilumab (or a bronchodilator, IL-33 antagonist, interleukin-4 receptor alpha antagonist, and / or interleukin-13 receptor antagonist generally) at a dose that exceeds the standard dose when the subject's FEV1-PS is below the threshold FEV1-PS. In some embodiments, the standard dose of dupilumab is 200 mg. In some embodiments, the amount of dupilumab that exceeds the standard dose exceeds 200 mg.

[0016] In some embodiments, the method further comprises administering to the subject having an FEV1-PS below a threshold FEV1-PS an interleukin-4 receptor alpha antagonist other than dupilumab and / or an interleukin-13 receptor antagonist. In some embodiments, the method further comprises administering to the subject having an FEV1-PS that is below a threshold FEV1-PS an IL-33 antagonist.

[0017] The present disclosure also provides a method of treating a subject having a pulmonary disease with a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist. In some embodiments, the subject having a pulmonary disease is treated with dupilumab. In some embodiments, the subject is administered or continues to be administered a standard dose of dupilumab (or generally a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist), and the subject has an FEV1-PS that is equal to or greater than a threshold FEV1-PS. In some embodiments, the subject's FEV1-PS has been previously determined. In some embodiments, the subject is administered or continues to be administered dupilumab (or generally, a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist) at a dose that is greater than the standard dose, and the subject has an FEV1-PS that is less than a threshold FEV1-PS. In some embodiments, the subject's FEV1-PS has been previously determined. In some embodiments, the standard dose of dupilumab is 200 mg. In some embodiments, the amount of dupilumab that is greater than the standard dose is greater than 200 mg. In some embodiments, the method further comprises administering an interleukin-4 receptor alpha antagonist and / or an interleukin-13 receptor antagonist other than dupilumab to the subject who has an FEV1-PS that is less than a threshold FEV1-PS. In some embodiments, the subject's FEV1-PS has been previously determined. In some embodiments, the method further comprises administering an IL-33 antagonist to the subject having an FEV1-PS that is below a threshold FEV1-PS. In some embodiments, the subject's FEV1-PS has been previously determined.

[0018] The disclosure also provides a method of determining whether a subject having or at risk of developing a pulmonary disease will respond adequately to treatment with dupilumab (or generally, a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist). The method includes determining or having determined the subject's FEV1-PS. The FEV1-PS includes a collection of multiple genetic variants associated with pre-bronchodilator FEV1. An FEV1-PS equal to or greater than a threshold FEV1-PS indicates that the subject will respond adequately to treatment with a standard dose of dupilumab (or generally, a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist). Alternatively, an FEV1-PS below the threshold FEV1-PS indicates that the subject is not responding adequately to treatment with standard doses of dupilumab (or generally, bronchodilators, IL-33 antagonists, interleukin-4 receptor alpha antagonists, and / or interleukin-13 receptor antagonists).

[0019] The present disclosure also provides methods of classifying subjects having or at risk of developing a pulmonary disease that will respond adequately to treatment with dupilumab (or generally, bronchodilators, IL-33 antagonists, interleukin-4 receptor alpha antagonists, and / or interleukin-13 receptor antagonists) by performing the methods described herein. The present disclosure also provides methods of selecting subjects having or at risk of developing a pulmonary disease for treatment with dupilumab (or generally, bronchodilators, IL-33 antagonists, interleukin-4 receptor alpha antagonists, and / or interleukin-13 receptor antagonists) by performing the methods described herein. The present disclosure also provides methods of improving efficacy of a pulmonary disease by performing the methods described herein.

[0020] Without being limited to any particular theory, it is believed that the FEV1-PS determined according to the methods presented herein allows for the identification of subjects who are likely to respond to therapeutic agents that treat or inhibit lung disease, including, but not limited to, bronchodilators, interleukin-4 receptor alpha antagonists and / or interleukin-13 receptor antagonists (such as dupilumab), or IL-33 antagonists. Subjects with an FEV1-PS above the threshold FEV1-PS may have a high FEV1 and therefore respond well to treatment with dupilumab. Such subjects may be treated with a standard dose of dupilumab or may continue to be treated. Subjects with an FEV1-PS below the threshold FEV1-PS may have a low FEV1 and therefore do not respond well to treatment with a standard dose of dupilumab. Such subjects may be treated with a dose of dupilumab above the standard dose or may be treated with a different therapeutic agent or combination of therapeutic agents. In some embodiments, a favorable therapeutic response to treatment with dupilumab (or, generally, a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist) is measured by an upper quartile FEV1.

[0021] In some embodiments, the methods disclosed herein are used to select a population of subjects or candidates for a clinical trial, e.g., a clinical trial, to determine whether a particular treatment or treatment regimen is effective against a pulmonary disease, such as asthma or COPD. In some embodiments, the selected candidates or subjects are divided into subgroups based on the genetic variants identified for each subject or candidate, and the method is used to determine whether a particular treatment or treatment regimen is effective for a particular group of subjects or genetic variants with a particular genetic variant. For example, the methods described herein can be used to determine the susceptibility of a population of subjects to a particular treatment or treatment regimen, and the population of subjects is selected based on the genetic variants identified in the subjects. In some embodiments, the desired group is a population that includes subjects or candidates with asthma or COPD. In some embodiments, the selected population of subjects or candidates are responders, i.e., the subjects or candidates respond to the treatment or treatment regimen.

[0022] In some embodiments, the methods described herein further include initiating treatment for the subject. Treatment can include bronchodilators, such as ICS, leukotriene modifiers, long-acting beta agonists (LABA), theophylline, combination inhalants containing both corticosteroids and LABAs, short-acting beta agonists, such as albuterol, ipratropium, oral corticosteroids, intravenous corticosteroids, allergy shots, allergy medications, omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and itepekimab, or any combination thereof. Initiating treatment can include devising a group-based treatment plan that corresponds to the calculated FEV1-PS for the subject. In some embodiments, the FEV1-PS predicts treatment efficacy or the subject's response to a treatment regimen. Thus, treatment can be determined or adjusted according to the FEV1-PS.

[0023] In some embodiments, initiating treatment involves modifying the dosage or regimen of a treatment that a subject with a pulmonary disease, such as asthma or COPD, is already receiving based on the FEV1-PS calculated for the subject. In some embodiments, initiating treatment involves replacing one therapeutic agent with another therapeutic agent based on the FEV1-PS. In some embodiments, initiating treatment involves starting a regimen of a second therapeutic agent in addition to a first therapeutic agent that the subject is already receiving. In some embodiments, initiating treatment involves starting administration of a therapeutic agent regimen to a previously untreated pulmonary disease subject.

[0024] Examples of therapeutic agents that can be used to treat asthma include, but are not limited to, ICS, leukotriene modifiers, long-acting beta agonists (LABAs), theophylline, combination inhalants containing both a corticosteroid and a LABA, short-acting beta agonists such as albuterol, ipratropium, oral corticosteroids, intravenous corticosteroids, allergy shots, allergy medications, omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and itepekimab, or any combination thereof.

[0025] In some embodiments, a therapeutic agent that increases FEV1 in asthma may be administered, including, but not limited to, an OCS, ICS, LABA, LAMA, SABA, SAMA, anti-leukotrienes (such as montelukast), theophylline, dupilumab, tezepelumab, omalizumab, mepolizumab, benralizumab, and reslizumab, or any combination thereof.

[0026] In some embodiments, the therapeutic agent is a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist. In some embodiments, the FEV1-PS predicts the therapeutic efficacy or the subject's response to a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist treatment. Thus, the bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist treatment can be determined or adjusted according to the calculated FEV1-PS for the subject.

[0027] In the methods described herein, the therapeutic agent (e.g., a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist) may be able to inhibit the activity of the respective protein or other substance in the cell, at least to a certain extent. This can be achieved by direct interaction of the compound with the given protein or substance ("direct inhibition"), or by interaction of the compound with other proteins or other substances inside or outside the cell that leads to at least partial inhibition of the activity of the protein or substance ("indirect inhibition"). Inhibition of protein activity can also be achieved by suppressing expression of the target protein. Techniques for inhibiting protein expression include, but are not limited to, antisense inhibition, siRNA-mediated inhibition, miRNA-mediated inhibition, ribozyme-mediated inhibition, DNA-directed RNA interference (DdRNAi), RNA-directed DNA methylation, transcription activator-like effector nuclease (TALEN)-mediated inhibition, zinc finger nuclease-mediated inhibition, aptamer-mediated inhibition, and CRISPR-mediated inhibition.

[0028] In some embodiments, the therapeutic agent (e.g., a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist) is an inhibitory nucleic acid molecule. In some embodiments, the inhibitory nucleic acid molecule comprises an antisense molecule, a small interfering RNA (siRNA) molecule, or a short hairpin RNA (shRNA) molecule. In some embodiments, the inhibitory nucleic acid molecule comprises an antisense molecule. In some embodiments, the inhibitory nucleic acid molecule comprises an siRNA molecule. In some embodiments, the inhibitory nucleic acid molecule comprises an shRNA molecule. In some embodiments, the therapeutic agent (such as a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist) is a small molecule.

[0029] In some embodiments, the IL-33 antagonist is an anti-IL-33 antibody or an antigen-binding portion thereof. In some embodiments, the IL-33 agonist is an anti-IL-33 receptor antagonist. In some embodiments, the interleukin-4 receptor alpha antagonist is an anti-interleukin-4 receptor alpha antibody or an antigen-binding fragment thereof. In some embodiments, the anti-interleukin-4 receptor alpha antagonist is an anti-interleukin-4 antibody or an antigen-binding fragment thereof. In some embodiments, the interleukin-13 receptor antagonist is an anti-IL-13 receptor antibody. In some embodiments, the interleukin-13 receptor antagonist is an anti-interleukin-13 antibody or an antigen-binding fragment thereof.

[0030] The term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains, inter-connected by disulfide bonds, and multimers thereof (e.g., IgM). Each heavy chain contains a heavy chain variable region (referred to herein as HCVR or V H The heavy chain constant region is C H 1. C H 2, and CH Each light chain comprises three domains: a light chain variable region (herein referred to as LCVR or V L The light chain constant region comprises one domain (C L 1) is included. H and V L The regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), flanked by more conserved regions, called framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments, the FRs of an anti-IL-33 antibody (or antigen-binding fragment thereof) or an anti-Interleukin-4 Receptor alpha (antigen-binding portion thereof) may be identical to the human germline sequence or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

[0031] In some embodiments, an "antibody" includes an antigen-binding fragment of a complete antibody molecule. As used herein, terms such as "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody include any naturally occurring, enzymatically derived, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies may be derived, for example, from complete antibody molecules using any suitable standard technique, such as proteolytic digestion, or recombinant genetic engineering techniques, including the manipulation and expression of DNA encoding the variable domains and optionally the constant domains of an antibody. Such DNA is readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated, chemically or using molecular biology techniques, for example, to place one or more variable and / or constant domains in a suitable configuration, or to introduce codons, create cysteine ​​residues, modify, add, or delete amino acids.

[0032] In some embodiments, the interleukin-4 receptor alpha antagonist specifically binds to human IL-4Rα and comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 1, a light chain variable region (LCVR) comprising SEQ ID NO: 2, a heavy chain complementarity determining region 1 (HCDR1) comprising SEQ ID NO: 3, a HCDR2 comprising SEQ ID NO: 4, a HCDR3 comprising SEQ ID NO: 5, a light chain complementarity determining region 1 (LCDR1) comprising SEQ ID NO: 6, a LCDR2 comprising SEQ ID NO: 7, and a LCDR3 comprising SEQ ID NO: 8. The full-length heavy chain of dupilumab is shown as SEQ ID NO: 9, and the full-length light chain is shown as SEQ ID NO: 10. Human anti-IL-4R antibodies can be generated as described in U.S. Patent No. 7,608,693.

[0033] In some embodiments, the IL-33 antagonist comprises itepekimab. In some embodiments, the interleukin-4 receptor alpha antagonist is dupilumab. In some embodiments, the interleukin-13 receptor antagonist is dupilumab. In some embodiments, the interleukin-4 receptor alpha antagonist and the interleukin-13 receptor antagonist are dupilumab.

[0034] In the context of this method, the additional therapeutically active ingredient(s), e.g., any of the agents listed above or derivatives thereof, may be administered immediately prior to, simultaneously with, or immediately following administration of the bronchodilator, IL-33 antagonist, interleukin-4 receptor alpha antagonist, and / or interleukin-13 receptor antagonist (for purposes of this disclosure, such administration regimes will be considered as administering the bronchodilator, IL-33 antagonist, interleukin-4 receptor alpha antagonist, and / or interleukin-13 receptor antagonist "in combination" with the additional therapeutically active ingredient). In some embodiments, the additional therapeutically active ingredient is considered to be administered "in combination with" the bronchodilator, IL-33 antagonist, interleukin-4 receptor alpha antagonist, and / or interleukin-13 receptor antagonist, despite the fact that the additional therapeutically active ingredient and the bronchodilator, IL-33 antagonist, interleukin-4 receptor alpha antagonist, and / or interleukin-13 receptor antagonist are administered by different routes. The methods include pharmaceutical compositions and methods of use thereof in which the bronchodilator, IL-33 antagonist, interleukin-4 receptor alpha antagonist, and / or interleukin-13 receptor antagonist are co-formulated with one or more of the additional therapeutically active ingredient(s) described herein.

[0035] In any of the embodiments described herein, the pulmonary disease may be any disease for which spirometry is used. In some embodiments, the pulmonary disease is an obstructive pulmonary disease, such as asthma, COPD, and forms of bronchiectasis (such as cystic fibrosis). In some embodiments, the pulmonary disease is a restrictive pulmonary disease, such as interstitial lung disease, including idiopathic pulmonary fibrosis. In any of the embodiments described herein, the pulmonary disease may be a disease, including, but not limited to, asthma, COPD, pulmonary fibrosis, chronic bronchitis, emphysema, acute bronchitis, cystic fibrosis, bacterial lung infections, mycobacterial infections, pneumonia, tuberculosis, including but not limited to tuberculosis caused by Mycobacterium tuberculosis, pulmonary edema, lung cancer, acute respiratory distress syndrome (ARDS), including but not limited to ARDS associated with COVID, pneumoconiosis, lung injury caused by chemical, biological, or radiological nuclear (CBRN) agents, black lung disease associated with exposure to coal dust, and asbestosis associated with exposure to asbestos. In some embodiments, the asthma may be, but is not limited to, mild asthma, moderate asthma, severe asthma, eosinophilic asthma with or without changes in immunoglobulin E levels, or oral corticosteroid-dependent asthma.In some embodiments, the asthma exacerbation may be annualized asthma exacerbation.In some embodiments, the pulmonary disease is asthma.In some embodiments, the pulmonary disease is COPD.

[0036] In some embodiments, subjects treatable by the methods of the present disclosure have had a pulmonary disease within the past 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 months. Subjects treatable by the methods of the present disclosure include subjects who have been hospitalized with asthma-related or COPD-related symptoms, and subjects who are currently hospitalized.

[0037] The evaluation using multiple genetic variants provides the advantage of increased predictive power. In some embodiments, the multiple genetic variants include single nucleotide polymorphisms (SNPs), insertions, deletions, structural variants, or copy number variations, or any combination thereof. In some embodiments, one or more of the genetic variants are SNPs. In some embodiments, one or more of the genetic variants are insertions. In some embodiments, one or more of the genetic variants are deletions. In some embodiments, one or more of the genetic variants are structural variants. In some embodiments, one or more of the genetic variants are copy number variations.

[0038] In some embodiments, subjects may be selected based on an FEV1-PS, where the FEV1-PS includes the sum (or weighted sum) of multiple genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1, and is calculated using at least about 150, at least about 500, at least about 1,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 250,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 1,500,000, at least about 2,000,000, at least about 2,500,000, at least about 3,000,000, at least about 5,000,000, or at least about 10,000,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1.

[0039] In some embodiments, the disclosure provides a method of determining FEV1-PS in a subject comprising identifying whether at least about 150, at least about 500, at least about 1,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 250,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 1,500,000, at least about 2,000,000, at least about 2,500,000, at least about 3,000,000, at least about 5,000,000, or at least about 10,000,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1, are present in a biological sample from the subject, wherein the presence of alleles associated with a pulmonary metric, such as pre-bronchodilator FEV1, increases FEV1-PS.

[0040] In some embodiments, the disclosure provides a method of determining FEV1-PS in a subject, the method comprising identifying whether genetic variants associated with a pulmonary metric such as pre-bronchodilator FEV1 are present in a biological sample from the subject, and calculating the subject's FEV1-PS based on the identified genetic variants, wherein the FEV1-PS is calculated by summing weighted scores associated with each identified genetic variant. The number of identified genetic variants can be at least about 150, at least about 500, at least about 1,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 250,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 1,500,000, at least about 2,000,000, at least about 2,500,000, at least about 3,000,000, at least about 5,000,000, or at least about 10,000,000 genetic variants.

[0041] In some embodiments, the disclosure provides a method of determining FEV1-PS in a subject, comprising identifying whether genetic variants associated with a pulmonary metric such as pre-bronchodilator FEV1 are present in a biological sample from the subject, wherein the identifying comprises measuring the presence of at least about 150, at least about 500, at least about 1,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 250,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 1,500,000, at least about 2,000,000, at least about 2,500,000, at least about 3,000,000, at least about 5,000,000, or at least about 10,000,000 genetic variants.

[0042] In some embodiments, the disclosure provides a method of determining FEV1-PS in a subject, comprising: determining at least about 2 genetic variants, at least about 10 genetic variants, at least about 25 genetic variants, at least about 50 genetic variants, at least about 100 genetic variants, at least about 150 genetic variants, at least about 200 genetic variants, at least about 500 genetic variants, at least about 1,000 genetic variants, at least about 2,000 genetic variants, at least about 5,000 genetic variants, at least about 10,000 genetic variants, at least about 20,000 genetic variants, at least about selecting about 50,000 genetic variants, at least about 75,000 genetic variants, at least about 100,000 genetic variants, at least about 500,000 genetic variants, at least about 1 million genetic variants, at least about 2 million genetic variants, at least about 2 million genetic variants, at least about 3 million genetic variants, at least about 5 million genetic variants, or at least about 10 million genetic variants; and identifying whether the genetic variants are present in a biological sample from the subject; and calculating an FEV1-PS based on the presence of the genetic variants.

[0043] In some embodiments, the plurality of genetic variants in the FEV1-PS determination includes at least 2 genetic variants associated with a pulmonary metric, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination includes at least 10 genetic variants associated with a pulmonary metric, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination includes at least 25 genetic variants associated with a pulmonary metric, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination includes at least 50 genetic variants associated with a pulmonary metric, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination includes at least 100 genetic variants associated with a pulmonary metric, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination includes at least 150 genetic variants associated with a pulmonary metric, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 1,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 10,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 100,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 1,000,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 2,000,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1.In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 2,500,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 3,000,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 5,000,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1. In some embodiments, the plurality of genetic variants in the FEV1-PS determination comprises at least 10,000,000 genetic variants associated with pulmonary metrics, e.g., pre-bronchodilator FEV1.

[0044] In some embodiments, the disclosure provides a method for selecting a subject or candidate for administration of a therapeutic agent to treat or inhibit a pulmonary disease, including, but not limited to, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist, comprising selecting from at least about 150, at least about 500, at least about 1,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 250,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 1,500,000, at least about 2,000, The present invention provides methods for determining whether at least about 1,000, at least about 2,500,000, at least about 3,000,000, at least about 5,000,000, or at least about 10,000,000 genetic variants are present in a biological sample from each subject or candidate, and calculating an FEV1-PS for each subject or candidate based on the identified genetic variants, and selecting the subject or candidate for administration of a therapeutic agent to treat or inhibit the pulmonary disease, including, but not limited to, an IL-33 antagonist, e.g., itepekimab, or an interleukin-4 receptor alpha antagonist or an interleukin-13 receptor antagonist, e.g., dupilumab.

[0045] In some embodiments, the disclosure provides a method for selecting a population of subjects or candidates for administration of a therapeutic agent to treat or inhibit a pulmonary disease, including, but not limited to, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist, comprising: detecting in a biological sample from each subject or candidate at least about 150, at least about 500, at least about 1,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 250,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 2,000,000, at least about 3,000,000, at least about 4,000,000, at least about 5,000,000, at least about 6,000,000, at least about 7,000,000, at least about 8,000,000, at least about 9,000,000, at least about 10,000,000, at least about 15,000,000, at least about 20,000,000, at least about 30,000,000, at least about 40,000,000, at least about 50,000,000, at least about 60,000,000, at least about 80,000,000, at least about 100,000, at least about 150,000, at least about 200,000, at least about 300,000, at least about 100,000, at least about 200,000, at least about 300,000, In one embodiment, the method includes determining whether at least about 1,500,000, at least about 2,000,000, at least about 2,500,000, at least about 3,000,000, at least about 5,000,000, or at least about 10,000,000 genetic variants are present, and calculating the FEV1-PS of each subject or candidate based on the identified genetic variants, and selecting the subject or candidate for administration of a therapeutic agent to treat or inhibit the pulmonary disease, including, but not limited to, a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist.

[0046] In some embodiments, the number of genetic variants identified is at least 2 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of genetic variants identified is at least 10 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of genetic variants identified is at least 25 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of genetic variants identified is at least 50 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of genetic variants identified is at least 100 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of genetic variants identified is at least 150 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of genetic variants identified is at least 500 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 1,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 2,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 5,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 10,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 20,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 50,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1.In some embodiments, the number of identified genetic variants is at least 75,000 genetic variants associated with a pulmonary metric such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 100,000 genetic variants associated with a pulmonary metric such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 500,000 genetic variants associated with a pulmonary metric such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 1,000,000 genetic variants associated with a pulmonary metric such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 2,000,000 genetic variants associated with a pulmonary metric such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 3,000,000 genetic variants associated with a pulmonary metric such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 5,000,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1. In some embodiments, the number of identified genetic variants is at least 10,000,000 genetic variants associated with a pulmonary metric, such as pre-bronchodilator FEV1.

[0047] In some embodiments, the genetic variants include any one or more of the variants listed in Table 1 (variant ids according to GRCh38 / hg38 human genome assembly coordinates).

[0048] [Table 1-1]

[0049] [Table 1-2]

[0050] As an exemplary method, FEV1-PS can be determined from data obtained from a GWAS related to a lung metric, such as pre-bronchodilator FEV1. For example, in a representative hypothetical GWAS, the GWAS could identify four genetic variants that are related to a lung metric, such as pre-bronchodilator FEV1. Each of the genetic variants may be related to one or more genes. Values ​​such as odds ratios can be calculated for each individual genetic variant. A particular subject's FEV1-PS can be determined by multiplying the logarithm of the individual odds ratios for each variant by the numerical effect allele (which is the number of copies of the genetic variant in the genome, i.e., either 0, 1, or 2), and then summing the resulting values. This type of determination can be illustrated by Table 2 below.

[0051] [Table 2]

[0052] Thus, the subject's FEV1-PS is the sum of the individual values ​​in the last column of the table, taking into account any number of genetic variants related to pulmonary metrics such as pre-bronchodilator FEV1. This simplified methodology for determining a subject's FEV1-PS is for illustrative purposes only and should not be construed as limiting in any way. The FEV1-PS in the above table is a weighted score, since each genetic variant may have a different weight depending on the particular odds ratio and numerical effect allele value.

[0053] In some embodiments, the present disclosure provides a method for assigning a risk group to a subject. The method includes: determining whether a genetic variant is present in a biological sample from a subject; calculating the subject's FEV1-PS based on the identified genetic variant; and assigning the subject to a risk group based on the FEV1-PS. FEV1-PS can be divided into, for example, upper quintile, upper-middle quintile, middle quintile, middle-lower quintile, and lower quintile, with the upper quintile of FEV1-PS corresponding to the highest genetic risk group and the lower quintile of FEV1-PS corresponding to the lowest genetic risk group. The number of identified genetic variants can be at least about 150, at least about 500, at least about 1,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 250,000, at least about 500,000, at least about 750,000, at least about 1,000,000, at least about 1,500,000, at least about 2,000,000, at least about 2,500,000, at least about 3,000,000, at least about 5,000,000, or at least about 10,000,000 genetic variants.In some embodiments, the threshold FEV1-PS is the upper quartile in the reference population.In some embodiments, the threshold FEV1-PS is the upper quintile in the reference population. In some embodiments, the threshold FEV1-PS is the upper decile within a reference population.

[0054] In some embodiments, the risk assessment includes the highest weighted FEV1-PS score, including but not limited to the top 50%, 55%, 60%, 70%, 80%, 90%, or 95% of FEV1-PS scores from the subject population. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the top 50, 55, 60, 70, 80, 90, or 95 percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the top 50 percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the top 55 percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the top 60 percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the top 65 percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the upper 70th percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the upper 75th percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the upper 80th percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the upper 85th percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the upper 90th percentile of FEV1-PS values. In some embodiments of the present disclosure, the threshold FEV1-PS is a value within the upper 95th percentile of FEV1-PS values.

[0055] In some embodiments, the identified genetic variants include the best genetic variants or genetic variants with a weighted score in the top 10, top 20, top 30, top 40, or top 50 percentile. In some embodiments, the identified genetic variants include the best genetic variants or genetic variants with a weighted score in the top 10 percentile. In some embodiments, the identified genetic variants include the best genetic variants or genetic variants with a weighted score in the top 20 percentile. In some embodiments, the identified genetic variants include the best genetic variants or genetic variants with a weighted score in the top 30 percentile. In some embodiments, the identified genetic variants include the best genetic variants or genetic variants with a weighted score in the top 40 percentile. In some embodiments, the identified genetic variants include the best genetic variants or genetic variants with a weighted score in the top 50 percentile.

[0056] In some embodiments, the identified genetic variants include genetic variants that have an association with asthma in the top 10%, top 20%, top 30%, top 40%, or top 50% of the p-value range. In some embodiments, the identified genetic variants include genetic variants that have an association with asthma in the top 10% of the p-value range. In some embodiments, the identified genetic variants include genetic variants that have an association with asthma in the top 20% of the p-value range. In some embodiments, the identified genetic variants include genetic variants that have an association with asthma in the top 30% of the p-value range. In some embodiments, the identified genetic variants include genetic variants that have an association with asthma in the top 40% of the p-value range. In some embodiments, the identified genetic variants include genetic variants that have an association with asthma in the top 50% of the p-value range.

[0057] In some embodiments, each of the identified genetic variants is about 10 -1 Below, about 10 -2 Below, about 10 -3 Below, about 10 -4 Below, about 10-5 Below, about 10 -6 Below, about 10 -7 Below, about 10 -8 Below, about 10 -9 Below, about 10 -10 Below, about 10 -11 Below, about 10 -12 Below, about 10 -13 Below, about 10 -14 Less than or equal to 10 -15 In some embodiments, the identified genetic variants include those with a p-value of 5×10 -8 Includes genetic variants with a p-value less than .

[0058] In some embodiments, the identified genetic variants include genetic variants having an association with the subject relative to the remainder of a reference population with an odds ratio (OR) of about 1.0 or more, about 1.5 or more, about 1.75 or more, about 2.0 or more, or about 2.25 or more, for the top up to 50% of the distribution, or about 1.5 or more, about 1.75 or more, about 2.0 or more, about 2.25 or more, about 2.5 or more, or about 2.75 or more. In some embodiments, the OR can be in the range of about 1.0 to about 1.5, about 1.5 to about 2.0, about 2.0 to about 2.5, about 2.5 to about 3.0, about 3.0 to about 3.5, about 3.5 to about 4.0, about 4.0 to about 4.5, about 4.5 to about 5.0, about 5.0 to about 5.5, about 5.5 to about 6.0, about 6.0 to about 6.5, or about 6.5 to about 7.0. In some embodiments, the subjects include those with FEV1-PS scores in the top decile, quintile, or tertile in a reference population.

[0059] In some embodiments, subjects are selected based on FEV1-PS alone. For example, for subjects or candidate subjects with FEV1-PS above a certain threshold, the subject is selected to start treatment or the candidate is included in a clinical trial. In some embodiments, the threshold for starting treatment or including in a clinical trial is determined in relative terms. For example, in some embodiments, the threshold FEV1-PS score is the top 50% in the reference population. In some embodiments, the threshold FEV1-PS score is the top 40% in the reference population. In some embodiments, the threshold FEV1-PS score is the top 30% in the reference population. In some embodiments, the threshold FEV1-PS score is the top 25% in the reference population. In some embodiments, the threshold FEV1-PS score is the top 20% in the reference population. In some embodiments, the threshold FEV1-PS score is the top 15% in the reference population. In some embodiments, the threshold FEV1-PS score is the top 10% (decile) in the reference population. In some embodiments, the threshold FEV1-PS score is the top 5% in the reference population.

[0060] In some embodiments, the identified genetic variants include the genetic variants with the highest genetic variant performance in the reference population, hi some embodiments, the genetic variant performance is calculated with respect to FEV1-PS based on statistical significance, strength of association, and / or probability distribution.

[0061] In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 100 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 200 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 500 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 1,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 3,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 5,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 7,500 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 10,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 12,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 15,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 20,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 30,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 50,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 70,000 subjects. In some embodiments, the reference population for the determination of relative FEV1-PS is at least about 100,000 subjects.

[0062] In some embodiments, the reference population is enriched for members of ancestral groups. In some embodiments, the ancestral groups are derived from a principal component analysis of ancestry. In some embodiments, the ancestral groups include European ancestral groups, African ancestral groups, mixed American ancestral groups, East Asian ancestral groups, or South Asian ancestral groups. In some embodiments, the ancestral groups are European. In some embodiments, the ancestral groups are African. In some embodiments, the ancestral groups are mixed American. In some embodiments, the ancestral groups are East Asian. In some embodiments, the ancestral groups are South Asian. In some embodiments, the ancestral groups are any mixture of any two or more of European, African, mixed American, East Asian, and South Asian populations. In some embodiments, members of the ancestral groups have self-reported membership in the ancestral groups. In some embodiments, members of the ancestral groups are assigned to ancestral groups based on genetic testing into the ancestral groups.

[0063] In some embodiments, multiple genetic variants are determined by calculating the performance of genetic variations in a reference population and selecting the best performing genetic variants. Numerous methodologies can be used to calculate FEV1-PS. In some embodiments, the performance of genetic variants is calculated in terms of the strength of association and / or probability distribution. In some embodiments, FEV1-PS is calculated using the LDPred or SBayesR method, or any other available method. In some embodiments, genetic variant scores are calculated using a PRS calculation method such as the LDPred method (or variations and / or versions thereof). LDPred is a Bayesian approach to calculate the posterior average effect for all variants based on prior (effect size in previous genome-wide association studies) and subsequent shrinkage based on linkage disequilibrium. LDPred creates a PRS using genome-wide variation with weights derived from a set of GWAS summary statistics. See Vilhjalmsson et al., Am. J. Hum. Genet., 2015, 97, 576-92. In some embodiments, alternative approaches to calculate gene variant scores can be used, including SBayesR (Lloyd-Jones, LR, world wide web at “biorxiv.org / content / biorxiv / early / 2019 / 01 / 17 / 522961.full.pdf”), Pruning and Thresholding (P&T) (Purcell, Nature, 2009, 460, 748-752), and Conditional Joint Analysis of Results (COJO) (Yang et al., Nat. Genet., 2012, 44, 369-375). SBayesR is a Bayesian approach similar to LDPred, but allows for more flexibility in posterior mean effects. Pruning and thresholding (P&T) is a method to determine the minimum p-value threshold between variants (the p-value associated with the variant from the source data file) and r 2 Requires that a threshold (a measure of linkage disequilibrium (LD)) be specified. P&T identifies the variant with the smallest p-value in each region and then compares the variants with the specified r 2 greater than r2 All other variants in the region with the value are "aggregated". In the PRS, the index variant represents all variants in the clamp (only the index variant is included in the PRS, all other variants are excluded). COJO is conceptually similar to P&T, but incorporates additional variants in a given LD block into the score if they show an independent contribution to disease risk after conditioning on the index variant. In some embodiments, the race and size of the subject are taken into account when determining FEV1-PS.

[0064] In some embodiments, the performance of the genetic variant is calculated using the LDPred method, where the ρ value is about 0.0001 to about 0.5. In some embodiments, the performance of the genetic variant is calculated using the LDPred method, where the ρ value is about 0.5. In some embodiments, the performance of the genetic variant is calculated using the LDPred method, where the ρ value is about 0.1. In some embodiments, the performance of the genetic variant is calculated using the LDPred method, where the ρ value is about 0.05. In some embodiments, the performance of the genetic variant is calculated using the LDPred method, where the ρ value is about 0.01. In some embodiments, the performance of the genetic variant is calculated using the LDPred method, where the ρ value is about 0.005. In some embodiments, the performance of the genetic variant is calculated using the LDPred method, where the ρ value is about 0.001. In some embodiments, the performance of the genetic variant is calculated using the LDPred method, where the ρ value is about 0.0005. In some embodiments, the potency of the genetic variants is calculated using the LDPred method, where the p value is about 0.0001. In some embodiments, the proportion of causal markers (p) is set to 0.001, and the multiple genetic variants include at least two genetic variants. In some embodiments, the FEV1-PS is calculated using a pruning and thresholding method. In some embodiments, the p value threshold is 5×10 -8 and r 2 In some embodiments, the p-value threshold is 5×10 -2 and r 2The value is 0.8.

[0065] In some embodiments, the method further comprises an initial step of obtaining a biological sample from the subject. The biological sample may contain whole cell viable cells and / or cell debris. The biological sample may contain (or be derived from) a "body fluid". The present disclosure encompasses embodiments in which the body fluid is selected from amniotic fluid, aqueous humor, vitreous, bile, serum, breast milk, cerebrospinal fluid, earwax (ear wax), chyle, chyme, endolymph, perilymph, exudate, feces, female ejaculate, gastric acid, gastric juice, lymph, mucus (including nasal discharge and phlegm), pericardial fluid, peritoneal fluid, pleural fluid, pus, lyum, saliva, sebum (skin oil), semen, phlegm, synovial fluid, sweat, tears, urine, vaginal secretions, vomit, and mixtures of one or more thereof. Biological samples include cell cultures, body fluids, and cell cultures from body fluids. Body fluids can be obtained from a mammalian organism, for example, by venipuncture, or other collection or sampling procedures. In some embodiments, the FEV1-PS is determined from a biological sample obtained from the subject, the biological sample comprising blood, semen, saliva, urine, feces, hair, teeth, bone, tissue, buccal swab, or cells. In some embodiments, the biological sample comprises blood.

[0066] In any of the embodiments described herein, a subject who responds adequately to treatment with dupilumab, or any bronchodilator, IL-33 antagonist, interleukin-4 receptor alpha antagonist, and / or interleukin-13 receptor antagonist, will have or experience a desired biological response, such as a therapeutic and / or prophylactic effect. In some embodiments, the therapeutic effect includes one or more of: reducing / reducing the severity of pulmonary disease, reducing / reducing the severity of pulmonary disease-related effects, delaying the onset of symptoms of pulmonary disease-related effects, reducing the severity of symptoms of pulmonary disease-related effects, reducing the severity of acute episodes, reducing the number of symptoms of pulmonary disease-related effects, reducing the latency of symptoms of pulmonary disease-related effects, improving symptoms of pulmonary disease-related effects, reducing secondary symptoms, preventing recurrence of pulmonary disease, reducing the number or frequency of recurrent episodes, increasing the latency between symptomatic episodes, increasing the time to sustained progression, promoting remission, inducing remission, increasing remission, accelerating recovery, or increasing the effectiveness of or reducing resistance to alternative therapies, and / or increasing the survival time of the affected host animal after administration of the agent or composition comprising the agent. The prophylactic effect can include completely or partially avoiding / inhibiting or delaying (e.g., completely or partially avoiding / inhibiting or delaying) the progression / progression of pulmonary disease in the affected host animal and increasing the survival time. Treatment of pulmonary disease includes treatment of a subject already diagnosed as having any form of pulmonary disease at any clinical stage or manifestation, delaying the onset or progression or severity or worsening of symptoms or signs of pulmonary disease, and / or preventing and / or reducing the severity of pulmonary disease.

[0067] In any of the embodiments described herein, the method may further include prescribing a bronchodilator, an IL-33 antagonist, an interleukin-4 receptor alpha antagonist, and / or an interleukin-13 receptor antagonist.

[0068] All patent documents, websites, other publications, accession numbers, etc. cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual document was specifically and individually indicated to be so incorporated by reference. Where various versions of a sequence are associated with accession numbers at different times, the version associated with the accession number at the effective filing date of this application is meant. Effective filing date means the earlier of the actual filing date or the filing date of the priority application to which the accession number refers, if applicable. Similarly, where different versions of publications, websites, etc. have been published at different times, the version last published at the effective filing date of the application is meant, unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the present disclosure may be used in combination with any other feature, step, element, embodiment, or aspect, unless otherwise indicated. Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

[0069] The following examples are provided to more fully describe the embodiments. They are intended to illustrate, not limit, the claimed embodiments. The following examples provide those skilled in the art with a disclosure and description of how the compounds, compositions, articles, devices and / or methods described herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of any claims. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some error and deviation can be accounted for. Unless otherwise indicated, parts are parts by weight, temperature is °C or is at ambient temperature, and pressure is at or near atmospheric pressure. EXAMPLES

[0070] Example 1: Generation of a Therapeutic Polygenic Score (FEV1-PS) Dataset: We generated a genome-wide FEV1-PS for European populations. The FEV1-PS consisted of 2.27 million variants. Individual SNP contributions were estimated from the GWAS using the SBayesR method.

[0071] PRS Algorithm Selection: We used the LDPred approach to generate FEV1-PS. LDPred is a Bayesian approach to PRS development that calculates the posterior mean effect (adjusted effect size) for all variants based on prior and LD information from a reference panel. To drive discovery, LDPred jointly models the effect size and variance for each marker, and effect sizes generated from LDPred differ from P&T in that it incorporates LD structure when shrinking effect sizes. The adjustment or shrinking of variant weights is based not only on the magnitude of association of the variant with the disease but also on the linkage disequilibrium (LD) between the variants. In the LDPred approach, 1000 Genomes Phase 3 Version 5 data was used for the LD reference panel.

[0072] Calculating PRS: From the LDPred approach, we generated a set of variants and their respective weights. For LDPred, the variant weights were the adjusted log odds ratios (posterior means). After weight generation, the process of score calculation and normalization was the same. For a set of i=1,..,M variants in j=1,…N patients, the PRS for patient j is

[0073]

number

[0074] B i is the log odds ratio for variant i, and x ij is the number of variant alleles carried by patient j in variant i (for imputed variants, allele dosage for variant i). Scores were standardized to ~N(0,1) by subtracting the mean PRS and dividing by the FEV1-PS standard deviation within each ancestral group.

[0075] PRS algorithm verification and validation: For each set of LDPred tuning parameters, the PRS was calculated and logistic regression was performed with the composite endpoint as the dependent variable and PRS, age, sex, genotyping array (UK Biobank only), and ancestry covariates as independent variables. Odds ratios (ORs) and areas under the curve (AUCs) per PRS standard deviation (SD) were reported for each model. LDPred with ρ=0.001 performed best and was used for the primary analysis.

[0076] Summary Bayesian Multiple Regression (SBayesR) is another Bayesian-based PRS approach that calculates the posterior mean effect (adjusted effect size) for all variants based on prior (effect size reported in summary source data) and LD information from a reference panel. Compared to LDPred, which utilizes a point normal distribution as a prior distribution, SBayesR utilizes a mixture normal distribution as a prior distribution to estimate the joint effect of weights across the whole genome. SBayesR calculates the posterior mean effect size using the MCMC Gibbs sampler.

[0077] Choosing a threshold to define high risk: High genetic risk was defined as patients within the 25th, 50th, 75th, and 100th percentiles of the distribution of FEV1-PS. This threshold was selected in a post-hoc analysis that evaluated high FEV1-PS thresholds in the 25th, 50th, 75th, and 100th percentile range.

[0078] Statistical analysis: Baseline disease and medical history characteristics were analyzed to assess the distribution of asthma risk factors by genetic risk status, high (>percentile threshold) versus low (≤percentile threshold). Continuous baseline characteristics were compared using t-tests, and binary or categorical characteristics were tested with chi-squared or Fisher's exact test.

[0079] result: The PRS in this study was developed using GWAS data from individuals of European ancestry. As GWAS data become available for more diverse populations, FEV1-PS is likely to improve over time in non-European populations.

[0080] The graphs shown in Figure 1 (Panels A and B) show that FEV1-PS was significantly associated with increased change in FEV1 at week 12 in both dupilumab- and placebo-treated European subjects. Covariates were age, sex, STUDYID (study identifier), ICS_FL (taking inhaled corticosteroids at baseline; yes / no), EOSBL_300FL (eosinophils >300 at baseline), ASMANUM_LOG (history of exacerbations in the previous year), HGTBL (height at baseline), FEV1BL, and PC1-4 (principal components 1-4). FEV1-PS was divided into quartiles and ranked from lowest to highest, with the numbers at the bottom of each bar being the number of subjects in each group and the numbers within each bar being the change in FEV1 values ​​at week 12. When FEV1-PS was applied to a population of dupilumab-treated subjects of European ancestry, it was observed that this FEV1-PS was significantly associated with better FEV1 improvement in both the dupilumab and placebo groups.

[0081] The graph shown in Figure 2 shows that FEV1-PS was significantly associated with longitudinal increase in change in FEV1 in both dupilumab- and placebo-treated European subjects. Covariates were age, sex, STUDYID, ICS_FL, EOSBL_300FL, ASMANUM_LOG, HGTBL, FEV1BL, and PC1-4. FEV1-PS was observed to be significantly associated with better FEV1 improvement in both dupilumab and placebo groups.

[0082] The graphs shown in Figure 3 (Panels A and B) show that FEV1-PS was not associated with higher annualized exacerbation rates in European subjects. Covariates were age, sex, STUDYID, ICS_FL, EOSBL_300FL, ASMANUM_LOG, HGTBL, FEV1BL, and PC1-4. FEV1-PS was divided into quartiles and ranked from lowest to highest, the numbers at the bottom of each bar are the number of subjects in each group, and the numbers within each bar are the change in annualized exacerbation rate.

[0083] The graphs shown in Figure 4 (Panels A and B) show that FEV1-PS determined from European samples in UKBiobank is significantly associated with pre-bronchodilator FEV1 in GHS_GSA European samples. For the graphs in the first panel, the numbers "10", "20", "30", "40", "50", "60", "70", "80", "90", "95", and "100" separate FEV1-PS into deciles ranked from lowest to highest, and the values ​​within the error bars are the values ​​of pre-bronchodilator FEV1 response values ​​subjected to rank-based inverse normal transformation (RINT). For the graphs in Panel B, the x-axis indicates the cutoff for the upper percentile of FEV1-PS, the y-axis indicates the relative difference in pre-bronchodilator FEV1 RINT values, and the numbers within the error bars are the p-values ​​comparing each top percentile cohort with each of the lower FEV1-PS percentile group combinations. The best performing method for FEV1-PS was found to be determined using the SBayesR method, which is another Bayesian method for estimating the contribution of single SNPs to traits and developing PS.

[0084] Figure 5 shows genome-wide FEV1-PS in asthma patients (GHS_GSA Europe subjects) and the proportion with exacerbations. A p-value of 9.17e-28 was observed. FEV1-PS was divided into quartiles and ranked from lowest to highest, and the numbers at the bottom of each bar are the number of subjects in each group.

[0085] Figure 6 shows genome-wide FEV1-PS in GHS_GSA Europe subjects versus asthma and COPD. Values ​​for asthma were associated with a p-value of 3.13e-25 and values ​​for COPD were associated with a p-value of 9.86e-29. In the graph in panel A, FEV1-PS is divided into quartiles and ranked from lowest to highest, the numbers at the bottom of each bar are the number of subjects in each group, and the numbers at the top represent the proportion of asthma patients from the total population. In the graph in panel B, FEV1-PS is divided into quartiles and ranked from lowest to highest, the numbers at the bottom of each bar are the number of subjects in each group, and the numbers at the top represent the proportion of COPD patients from the total population.

[0086] Figure 7 shows the genome-wide FEV1-PS (GWAS based on FEV1 values) developed in GHS_GSA European patients without asthma and COPD. The value of the exacerbation rate in asthma patients was associated with a p-value of 4.14e-02. FEV1-PS was divided into quartiles and ranked from lowest to highest, the numbers at the bottom of each bar are the number of subjects in each group, and the numbers at the top of each graph are the values ​​of the exacerbation rate in asthma patients.

[0087] FIG. 8 (Panels A and B) shows genome-wide FEV1-PS (GWAS based on FEV1 values) developed in GHS_GSA European patients without asthma and COPD. The percentage of asthmatics was associated with a p-value of 1.99e-08 and the percentage of COPD was associated with a p-value of 2.56e-14. In the graphs in Panel A, FEV1-PS is divided into quartiles and ranked from lowest to highest, the numbers at the bottom of each bar are the subjects in each group, and the numbers at the top of each graph are the percentage of asthmatics from the total population. In the graphs in Panel B, FEV1-PS is divided into quartiles and ranked from lowest to highest, the numbers at the bottom of each bar are the subjects in each group, and the numbers at the top of each graph are the percentage of COPD from the total population.

[0088] In addition to those described herein, various modifications of the described subject matter will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank accession numbers, etc.) is incorporated herein by reference in its entirety.

Claims

1. 1. A method of treating a subject having or at risk of developing a pulmonary disease with a therapeutic agent that treats or inhibits a pulmonary disease, comprising: determining or having determined the subject's FEV1 polygenic score (FEV1-PS), the FEV1-PS comprising a collection of multiple genetic variants associated with pre-bronchodilator FEV1; and administering or continuing to administer a standard dose of the therapeutic agent that treats or inhibits a pulmonary disease if the subject's FEV1-PS is equal to or greater than a threshold FEV1-PS; or administering, if the subject's FEV1-PS is below the threshold FEV1-PS, a dose greater than a standard dose of the therapeutic agent that treats or inhibits a pulmonary disease.

2. 1. A method for determining whether a subject having or at risk of developing a pulmonary disease will respond adequately to treatment with a therapeutic agent that treats or inhibits the pulmonary disease, comprising: determining or having determined the subject's FEV1 polygenic score (FEV1-PS), wherein the FEV1-PS comprises a collection of multiple genetic variants associated with pre-bronchodilator FEV1; an FEV1-PS equal to or greater than the threshold FEV1-PS indicates that the subject will respond adequately to treatment with the therapeutic agent that treats or inhibits the pulmonary disease at a standard dose; or The method, wherein an FEV1-PS below a threshold FEV1-PS indicates that the subject does not respond adequately to treatment with a standard dose of the therapeutic agent that treats or inhibits a pulmonary disease.

3. 3. The method of claim 1 or 2, wherein the pulmonary disease is an obstructive pulmonary disease.

4. 3. The method of claim 1 or 2, wherein the pulmonary disease is a restrictive pulmonary disease.

5. 3. The method of claim 1 or 2, wherein the pulmonary disease is asthma.

6. 3. The method of claim 1 or 2, wherein the pulmonary disease is chronic obstructive pulmonary disease (COPD).

7. 3. The method of claim 1 or 2, wherein the lung disease is pulmonary fibrosis.

8. The method of any one of claims 1 to 7, wherein the therapeutic agent for treating or inhibiting a pulmonary disease is an interleukin-4 receptor alpha antagonist and / or an interleukin-13 receptor antagonist.

9. The method of claim 8, wherein the interleukin-4 receptor alpha antagonist and / or the interleukin-13 receptor antagonist is dupilumab.

10. The method of any one of claims 1 to 7, wherein the therapeutic agent for treating or inhibiting a pulmonary disease is an IL-33 antagonist.

11. The method of claim 10, wherein the IL-33 antagonist is itepekimab.

12. The method of any one of claims 1 to 7, wherein the therapeutic agent for treating or inhibiting a pulmonary disease is a bronchodilator.

13. 13. The method of claim 12, wherein the bronchodilator is an inhaled corticosteroid (ICS).

14. 13. The method of claim 12, wherein the bronchodilator is a long-acting beta agonist (LABA).

15. 15. The method of any one of claims 1 and 3-14, comprising administering an interleukin-4 receptor alpha antagonist and / or an interleukin-13 receptor antagonist to a subject having an FEV1-PS that is below the threshold FEV1-PS.

16. 16. The method of claim 15, wherein the interleukin-4 receptor alpha antagonist and / or the interleukin-13 receptor antagonist is dupilumab.

17. 15. The method of any one of claims 1 and 3-14, comprising administering an interleukin-4 receptor alpha antagonist and / or an interleukin-13 receptor antagonist other than dupilumab to a subject having an FEV1-PS that is below the threshold FEV1-PS.

18. 15. The method of any one of claims 1 and 3-14, comprising administering an IL-33 antagonist to a subject having an FEV1-PS that is below the threshold FEV1-PS.

19. 19. The method of claim 18, wherein the IL-33 antagonist is itepekimab.

20. 15. The method of any one of claims 2 to 14, further comprising administering an interleukin-4 receptor alpha antagonist other than dupilumab and / or an interleukin-13 receptor antagonist to the subject having an FEV1-PS that is below the threshold FEV1-PS.

21. 21. The method of claim 20, wherein the interleukin-4 receptor alpha antagonist and / or the interleukin-13 receptor antagonist is dupilumab.

22. 15. The method of any one of claims 1 and 3-14, further comprising administering an IL-33 antagonist to the subject having an FEV1-PS that is below the threshold FEV1-PS.

23. 23. The method of claim 22, wherein the IL-33 antagonist is itepekimab.

24. The method of any one of claims 1 to 23, wherein the threshold FEV1-PS is the upper quartile within a reference population.

25. The method of any one of claims 1 to 23, wherein the threshold FEV1-PS is the upper quintile within a reference population.

26. The method of any one of claims 1 to 23, wherein the threshold FEV1-PS is the top decile within a reference population.

27. The method of any one of claims 24 to 26, wherein the reference population comprises at least 100 subjects.

28. The method of any one of claims 24 to 26, wherein the reference population comprises at least 1,000 subjects.

29. The method of any one of claims 24 to 26, wherein the reference population comprises at least 5,000 subjects.

30. The method of any one of claims 24 to 26, wherein the reference population comprises at least 10,000 subjects.

31. The method of any one of claims 24 to 30, wherein the reference population is enriched for members of ancestral groups.

32. 32. The method of claim 31 , wherein the ancestral groups comprise European ancestry, African ancestry, mixed American ancestry, East Asian ancestry, or South Asian ancestry.

33. 33. The method of claim 31 or 32, wherein the members of the ancestral group have self-reported membership in the ancestral group.

34. 33. The method of claim 31 or 32, wherein the members of the ancestral group are determined by genetic testing for ancestry.

35. 35. The method of any one of claims 1 to 34, wherein the plurality of genetic variants comprises single nucleotide polymorphisms, insertions, deletions, structural variants, or copy number variations, or any combination thereof.

36. 36. The method of any one of claims 1 to 35, wherein the plurality of genetic variants is determined by calculating the performance of genetic variants in the reference population and selecting the best performing genetic variants.

37. 37. The method of claim 36, wherein the performance of the genetic variants is calculated in terms of strength of association and / or probability distribution.

38. The method of any one of claims 1 to 35, wherein the FEV1-PS is calculated using the LDPred or SBaye'sR method.

39. The method of any one of claims 1 to 35, wherein the FEV1-PS is calculated using a pruning and thresholding method.

40. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least two genetic variants.

41. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 10 genetic variants.

42. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 25 genetic variants.

43. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 50 genetic variants.

44. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 100 genetic variants.

45. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 150 genetic variants.

46. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 1,000 genetic variants.

47. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 10,000 genetic variants.

48. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 100,000 genetic variants.

49. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 1,000,000 genetic variants.

50. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 2,000,000 genetic variants.

51. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 5,000,000 genetic variants.

52. 40. The method of any one of claims 1 to 39, wherein the plurality of genetic variants comprises at least 10,000,000 genetic variants.

53. 53. The method of any one of claims 1-52, wherein the FEV1-PS is determined from a biological sample obtained from the subject, the biological sample comprising blood, semen, saliva, urine, faeces, hair, teeth, bone, tissue, cheek swab, or cells.

54. 54. The method of claim 53, wherein the biological sample comprises blood.